This is to inform that due to some circumstances beyond the organizer control, “International Conference on Medicinal Chemistry, Computer Aided Drug Design and Delivery” (MCADD 2023) Hybrid event during September 14-16, 2023 at Valencia, Spain has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at medicinal-chemistry@magnusconference.com or call + 1 (702) 988 2320.
The term "rational drug design" refers to the process of creating drug molecules that bind to a certain target (e.g. protein, nucleic acid). It depends on prior knowledge about the target's structure, function, and mechanism, reducing the need to test hundreds of molecules at random. Drug development is a difficult, expensive, and time-consuming process, albeit it has been sped up thanks to the development of computational tools and approaches. Because most of the medications produced using structure guided methodologies have been demonstrated to have substantial hazardous side effects, the present target-based drug design methodology is insufficient. Otherwise, these medications would have been an excellent choice for disease treatment. As a result, rational drug development would necessitate a multidisciplinary approach. The discipline of rational drug design is a fascinating and rapidly expanding one. The field's viability is ensured by its impact on quality of life and health.
Title : A qsar survey on tyrosine kinase inhibitors
Atefeh Hajiagha Bozorgi, Faculty of pharmacy, Iran (Islamic Republic of)
Title : Abbott diagnostics: COVID-19 inactivation, nucleocapsid antigen automated immunoassay development, and variant testing for automated and lateral flow assays binaxnow™ and panbio™
Philip M Hemken, Abbott Laboratories, United States
Title : Synthesis, antibacterial activity of 3-amino 5-methoxyl-2-methyl quinazolin-4(3H)-one an amino-6-methoxyl-2-methyl of 4H–benzo[d] [1,3]–oxazine–4–one
Osarumwense Peter Osarodion, Ondo State University of Sciences and Technology, Nigeria
Title : Tackling mycobacterium tuberculosis resistance with tailored isatin-pyrimidine hybrids enoyl acyl carrier protein reductase (Inha)
Amgad Albohy, The British University in Egypt (BUE), Egypt
Title : Transition metal complexes/Organometallic compounfs as anticancer drugs
Prakash kinthda, Nims university,jaipur,rajasthan, India
Title : New n-ribosides and n-mannosides of rhodanine derivatives with anticancer activity on leukaemia cell line: Design, synthesis, dft and molecular modelling studies
Ahmed, Kafrelsheikh University, Egypt